CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...
Phase 3
Orlando, Florida, United States and 60 other locations
resectable or borderline resectable, previously untreated pancreatic adenocarcinoma. The primary objective of this study is to investigate t...
Phase 2
Orlando, Florida, United States and 3 other locations
for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for ...
Phase 3
Orlando, Florida, United States and 197 other locations
as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma...
Phase 2
Orlando, Florida, United States and 47 other locations
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with pre...
Phase 2
Clermont, Florida, United States and 32 other locations
The goal of this clinical trial is to test an experimental treatment (immunotherapy) in pancreatic cancer patients. The main research objectives are:...
Phase 1
Orlando, Florida, United States and 14 other locations
after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...
Phase 3
Orlando, Florida, United States and 138 other locations
and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...
Phase 3
Orlando, Florida, United States and 165 other locations
unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Why is this study being done? SPOTLIGHT is a new clinical st...
Phase 3
Orlando, Florida, United States and 219 other locations
A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
Phase 1, Phase 2
Lady Lake, Florida, United States and 15 other locations
Clinical trials
Research sites
Resources
Legal